Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals

214.95
-19.96
(-8.50%)
Market Cap
1,430.00 Cr
EPS
8.26
PE Ratio
33.51
Dividend Yield
1.16 %
Industry
Healthcare
52 Week High
328.04
52 Week Low
158.62
PB Ratio
5.96
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Jagsonpal Pharmaceuticals Limited appointed Mr. Amrut Medhekar as Chief Operating Officer effective September 04, 2025. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Medhekar brings over 28 years of experience in sales, marketing, and business operations within the pharmaceutical sector. He holds an MBA in Marketing from Jiwaji University and completed a certificate course in General Management from IIM Ahmedabad. Previously, he served as CEO – Business Operations at Akums Drugs & Pharmaceuticals Limited and held senior leadership positions at Torrent Pharmaceuticals Ltd, Ranbaxy Ltd, Zydus Life Sciences Ltd, and Wockhardt Ltd. Medhekar is not related to any Director or Key Managerial Personnel of the company.
positive
Jagsonpal Pharmaceuticals delivered robust quarterly performance with revenue rising 23% year-on-year to Rs. 75.5 crores, driven by strong brand equity and focused marketing. The company's PAT doubled to over Rs. 108 million with net margins improving 560 basis points to 14.3%. Operating EBITDA before ESOP grew 24% to Rs. 157 million with margins at 20.8%. The company improved its Gynae CVM ranking to No. 7 as per CMARC and maintains top 5 positions in 14 of its top 15 brands. Cash position strengthened to Rs. 161 crores, an increase of Rs. 153 million over the previous quarter. The company terminated CFO Sachin Jain during probation period for misconduct. Yash Pharma acquisition contributed approximately Rs. 12 crores to topline versus Rs. 3.5 crores last year. Management maintains 15% growth guidance for the year and expects 100-150 basis points EBITDA margin expansion. The company operates with around 900-1000 medical representatives and focuses on subchronic therapeutic segments with roughly 50% business from gynae therapy.
neutral
Jagsonpal Pharmaceuticals Makes Q1 FY26 Earnings Call Recording Available OnlineJul 28, 2025
Jagsonpal Pharmaceuticals Limited has made the audio recording of their Q1 FY26 earnings conference call available on their company website. The call was held on July 28, 2025 at 3:00 P.M. to discuss Q1 FY26 financial results. The recording can be accessed through the investor relations section of the company's website at their earnings calls page.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,586.70
#1 3,80,702.50
33.18
#1 54,729.00
9.71
#1 10,980
-19.84
51.86
5,689.50
1,51,038.30
65.50
9,712.00
18.67
2,191
26.74
36.39
1,499.40
1,21,107.70
22.45
28,409.50
7.12
5,291
9.88
38.89
3,561.00
1,20,520.40
59.72
11,539.40
6.99
1,911
19.91
42.61
1,253.10
1,04,580.10
#1 18.40
33,741.20
16.73
5,725
1.26
46.51
2,482.90
1,02,476.40
54.18
12,744.20
#1 20.90
2,007
-18.14
44.66
975.00
98,107.80
21.07
23,511.00
18.55
4,615
2.60
50.50
1,919.80
87,676.40
23.72
22,909.50
13.74
3,306
#1 51.64
46.16
5,433.00
64,959.70
28.53
13,458.30
3.70
2,216
21.39
61.31
1,090.00
63,307.40
18.84
32,345.60
9.43
3,484
-10.24
53.78
Forecast
Actual
Growth Rate
Revenue Growth
27.02 %
Net Income Growth
146.22 %
Cash Flow Change
-24.62 %
ROE
92.41 %
ROCE
81.03 %
EBITDA Margin (Avg.)
44.20 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
138
144
144
127
168
161
192
221
242
218
277
316
Expenses
129
132
138
138
158
150
169
193
203
186
218
228
EBITDA
9
13
6
-11
11
11
24
29
40
32
59
88
Operating Profit %
6 %
8 %
4 %
-9 %
6 %
5 %
10 %
12 %
14 %
11 %
19 %
19 %
Depreciation
3
3
2
0
1
1
1
2
1
2
8
9
Interest
5
5
3
1
1
1
1
0
0
1
1
1
Profit Before Tax
2
4
14
-12
9
9
22
27
35
30
70
77
Tax
1
1
3
-0
2
2
5
8
8
7
15
15
Net Profit
1
3
12
-12
7
8
17
19
27
23
55
61
EPS in ₹
0.45
1.24
4.53
-4.41
2.75
3.00
6.51
7.20
10.20
8.49
8.26
11.60

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
154
159
143
130
136
147
164
164
195
217
278
Fixed Assets
52
52
22
21
22
22
26
23
24
9
95
Current Assets
96
101
110
95
98
95
121
109
165
199
161
Capital Work in Progress
0
0
0
3
4
4
0
0
0
0
0
Investments
0
0
0
0
0
11
15
51
1
0
0
Other Assets
102
108
121
106
110
109
123
91
170
208
184
Total Liabilities
154
159
143
130
136
147
164
164
195
217
278
Current Liabilities
55
57
29
29
28
33
40
27
28
19
26
Non Current Liabilities
4
4
3
3
3
3
2
5
9
11
12
Total Equity
95
98
110
98
105
111
122
133
159
187
240
Reserve & Surplus
82
85
97
85
91
98
109
120
146
174
226
Share Capital
13
13
13
13
13
13
13
13
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
2
1
5
-6
24
-1
19
-36
-12
2
Investing Activities
-1
-2
41
-3
-1
-11
-2
-26
-58
-25
Operating Activities
4
9
-3
-2
31
11
28
7
47
35
Financing Activities
-1
-6
-34
-1
-6
-1
-7
-18
-1
-9

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
70.34 %
70.34 %
70.34 %
70.34 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.48 %
68.09 %
68.04 %
67.97 %
67.81 %
67.78 %
67.65 %
FIIs
0.00 %
0.00 %
0.11 %
0.20 %
0.00 %
0.00 %
0.13 %
0.00 %
0.00 %
0.00 %
0.38 %
0.00 %
0.73 %
1.10 %
2.30 %
2.10 %
2.10 %
2.18 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.28 %
0.77 %
0.83 %
0.83 %
0.83 %
0.00 %
0.85 %
0.85 %
0.11 %
0.00 %
0.00 %
0.05 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.67 %
26.08 %
23.71 %
23.71 %
22.92 %
25.27 %
22.78 %
21.11 %
22.23 %
22.84 %
21.99 %
21.94 %
20.69 %
20.79 %
20.38 %
20.64 %
20.94 %
24.26 %
Others
2.98 %
3.57 %
5.83 %
5.75 %
8.36 %
6.02 %
8.10 %
9.40 %
8.23 %
7.62 %
8.09 %
9.58 %
9.64 %
9.22 %
9.24 %
9.45 %
9.17 %
5.86 %
No of Share Holders
0
12,546
14,655
14,353
20,031
17,100
16,194
14,952
14,084
13,782
16,041
15,785
16,282
15,748
15,633
18,471
21,085
22,899

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.1 0.1 0.1 0.25 0.5 1 4 5 5 2.5
Dividend Yield (%) 0.66 0.93 0.95 3.56 1.57 0.8 3.45 4.52 2.3 1.16

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
24 Sept 2021 DIVIDEND Dividend
₹ 1.00 /share
22 Sept 2021 61.54 61.64
01 Nov 2021 DIVIDEND Dividend
₹ 4.00 /share
29 Oct 2021 64.98 69.88
17 Jun 2022 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
17 Jun 2022 118.24 111.40
21 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
21 Aug 2023 141.58 183.34
06 Sept 2024 DIVIDEND Dividend
₹ 5.00 /share
06 Sept 2024 144.42 167.08
18 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Sept 2024 144.54 164.02
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 181.68 183.76
23 Oct 2024 SPLIT Split
2:5
08 Jan 2025 183.76 183.76
22 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 Jan 2025 215.25 222.00
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 May 2025 232.50 250.05
26 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 Jul 2025 262.50 263.29
12 Sept 2025 DIVIDEND Dividend
₹ 2.50 /share
12 Sept 2025 250.05 247.82
24 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2025 263.29 241.89

Announcements

Closure of Trading Window1 day ago
Shareholder Meeting / Postal Ballot-Scrutinizers Report1 day ago
Shareholder Meeting / Postal Ballot-Outcome of AGM3 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication8 days ago
Reg. 34 (1) Annual Report.8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 04, 2025
Letter To Shareholders For Annual Report Web-Link And PathSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Business Responsibility and Sustainability Reporting (BRSR)Sep 01, 2025
Notice Of 46Th Annual General Meeting Of The CompanySep 01, 2025
Reg. 34 (1) Annual Report.Sep 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 08, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 26, 2025
The 46Th Annual General Meeting Of The Company Will Be Held On September 24 2025 Dividend- Record Date Will Be September 12 2025 Jul 26, 2025
Results- Financial Results For The Quarter Ended June 30 2025Jul 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting Along With Unaudited Financial Results For The Quarter Ended June 30 2025Jul 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Board Meeting Intimation for Consideration And Approval Of Un- Audited Financial Results For The Quarter Ended June 30 2025Jul 23, 2025
Announcement under Regulation 30 (LODR)-CessationJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 11, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
Termination Of Business Transfer Agreement - Disclosure Under Regulation 30 Of SEBI Listing RegulationsMay 06, 2025
Corporate Action-Board approves DividendMay 06, 2025
Audited (Standalone) Financial Results For The Year Ended March 31 2025May 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 06 2025 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Board Meeting Intimation for Consideration Of Financial Results For The Quarter And Year Ended March 31 2025 And Recommendation Of Dividend If Any For The Financial Year Ended March 31 2025.Apr 29, 2025
Clarification On Significant Increase In The VolumeApr 28, 2025
Clarification On Significant Increase In Volume Of Security Of The Company Required By NSEApr 28, 2025

Technical Indicators

RSI(14)
Neutral
30.93
ATR(14)
Volatile
10.34
STOCH(9,6)
Oversold
18.80
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-1.89
ADX(14)
Weak Trend
15.35
UO(9)
Bearish
33.43
ROC(12)
Downtrend And Accelerating
-12.28
WillR(14)
Oversold
-88.62

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%